
Hoth Therapeutics (HOTH) Stock Forecast & Price Target
Hoth Therapeutics (HOTH) Analyst Ratings
Bulls say
Hoth Therapeutics Inc. is effectively pursuing a dual-track strategy in both supportive oncology and metabolic diseases, which enhances its potential for incremental value generation through the advancement of joint venture programs. Clinical data indicating that over 65% of participants experienced reductions in pain and pruritus from their treatments highlights significant therapeutic efficacy and supports the viability of its lead asset, HT-001. Additionally, the company's second quarter 2025 results demonstrate disciplined expense management while progressing the development of HT-001, reinforcing a foundational financial discipline that bodes well for future growth.
Bears say
Hoth Therapeutics Inc. reported zero revenues for the second quarter of 2025, which continues to raise concerns regarding the company's revenue generation capabilities. Total operating expenses were $2.2 million, a decrease from $3.4 million in the previous quarter, yet the firm still incurred a net loss of $2.2 million, translating to a loss of $(0.17) per share. The absence of revenue coupled with ongoing losses highlights the financial challenges Hoth faces as it advances its clinical-stage candidates.
This aggregate rating is based on analysts' research of Hoth Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Hoth Therapeutics (HOTH) Analyst Forecast & Price Prediction
Start investing in Hoth Therapeutics (HOTH)
Order type
Buy in
Order amount
Est. shares
0 shares